Vanguard Capital Management Acquires 5.11% Passive Stake in Sarepta Therapeutics Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.11% stake in Sarepta Therapeutics Inc (SRPT). The filing indicates that as of March 31, 2026, Vanguard beneficially owns 5,369,116 shares of common stock. This represents a significant increase from a previous position of zero, crossing the 5% ownership threshold that triggers a Schedule 13G filing. Vanguard reports sole dispositive power over all 5,369,116 shares, while holding sole voting power over 790,881 shares. The filing includes holdings across various affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. No other single person's interest in these securities exceeds 5%. This passive investment reflects Vanguard's expanded institutional footprint in the Cambridge-based biotechnology firm.